Canada-based biotech firm Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) has lost its head of psychedelic medicine, but due to the loss, it gained full ownership in one of its clinics.
Dr. Ben Sessa resigned his position as head of psychedelic medicine at the company, effective April 13, Awakn disclosed in a press release. As part of the exit, Sessa is transferring his 49% ownership in Awakn Bristol Limited, with Awakn Clinics Bristol in England, to Awakn Life Sciences Inc., giving the company 100% ownership in the British psychedelics clinic.
In the same press release, Awakn announced that it had commenced treatments for alcohol use disorder with patients at a Manhattan facility run by Nushama Inc., one of Awakn’s licensing partners for its product line of Awakn Kare.
And on March 1, Awakn opened Awakn Clinics Trondheim in Norway for ketamine-assisted therapy. The opening marks the company’s fourth clinic globally and its second in Norway.
Awakn made headlines in February when the company was accused by OTC Markets group of running a stock promotion scheme, an allegation it denied.
